Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University, El-Guiesh Street, El-Gharbia Government, Tanta, 31527, Egypt.
Inflammopharmacology. 2024 Dec;32(6):3729-3738. doi: 10.1007/s10787-024-01567-z. Epub 2024 Sep 28.
The clinical presentations of Parkinson's disease (PD), a chronic neurodegenerative condition, include bradykinesia, hypokinesia, stiffness, resting tremor, and postural instability. Recently, neuroinflammation is involved in pathogenesis of PD. Application of nonsteroidal anti-inflammatory drugs captured attention to treat these neuroinflammation.
To investigate the possible effectiveness of celecoxib in patients with PD treated with conventional treatment.
Sixty outpatients who fulfilled the inclusion requirements for PD were enrolled in this randomized, prospective, and controlled study. The patients were allocated into two groups at random (n = 30); the control group received standard PD treatment, consisting of levodopa/carbidopa, and the celecoxib group received standard PD treatment plus celecoxib. A neurologist evaluated each patient at the beginning of the treatment and after 6 months. Assessment of Unified Parkinson's disease rating scale (UPDRS) for each patient. Before and after treatment, α -synuclein (α-Syn), tumor necrosis factor alpha (TNF-α), Toll like receptors-4 (TLR-4), nuclear factor erythroid 2-related factor 2 (Nrf-2) and brain-derived neurotropic factor (BDNF) were assessed. Paired and unpaired t tests were used to assess statistical significance within and between groups respectively.
The celecoxib group exhibited a significant and statistical reduction in the level of measured parameters by unpaired t test as followed: TLR-4 (p = 0.004), TNF-α (p = 0.042), and α-Syn (p = 0.004) apart from a significant increase in BDNF (p = 0.0005) and Nrf-2 (p = 0.004), in comparison with the control group. Also, UPDRS was significantly decreased in celecoxib group (p < 0.05).
Celecoxib could be a promising adjuvant therapy in managing patients with PD.
NCT05962957.
帕金森病（PD）是一种慢性神经退行性疾病，其临床特征包括运动迟缓、运动减少、僵硬、静止性震颤和姿势不稳。最近，神经炎症参与了 PD 的发病机制。非甾体抗炎药的应用引起了人们对治疗这些神经炎症的关注。
研究塞来昔布在接受常规治疗的 PD 患者中的可能疗效。
本随机、前瞻性、对照研究纳入了 60 名符合 PD 纳入标准的门诊患者。患者被随机分为两组（n=30）；对照组接受标准 PD 治疗，包括左旋多巴/卡比多巴，塞来昔布组接受标准 PD 治疗加塞来昔布。一名神经科医生在治疗开始时和 6 个月后对每位患者进行评估。评估每位患者的统一帕金森病评定量表（UPDRS）。治疗前后，评估α-突触核蛋白（α-Syn）、肿瘤坏死因子-α（TNF-α）、Toll 样受体 4（TLR-4）、核因子红细胞 2 相关因子 2（Nrf-2）和脑源性神经营养因子（BDNF）。采用配对和非配对 t 检验分别评估组内和组间的统计学意义。
与对照组相比，塞来昔布组的 TLR-4（p=0.004）、TNF-α（p=0.042）和 α-Syn（p=0.004）的测量参数水平显著降低，BDNF（p=0.0005）和 Nrf-2（p=0.004）水平显著升高，差异有统计学意义。此外，塞来昔布组的 UPDRS 显著降低（p<0.05）。
塞来昔布可能是治疗 PD 患者的一种有前途的辅助治疗方法。
NCT05962957。
